*P <.05 † GLP-1(7-36 amide) infused at 1.2 pmol/kg/min for 240 min Adapted from Nauck MA, et al. Diabetologia. 1993;36:741–744. Το GLP-1 αποκαθιστά τη
{"Image DocumentName": "\u03a4\u03bf GLP-1 \u03b1\u03c0\u03bf\u03ba\u03b1\u03b8\u03b9\u03c3\u03c4\u03ac \u03c4\u03b7\u03bd \u03ad\u03ba\u03ba\u03c1\u03b9\u03c3\u03b7 \u03c4\u03b7\u03c2 \u03b9\u03bd\u03c3\u03bf\u03c5\u03bb\u03af\u03bd\u03b7\u03c2 \u03ba\u03b1\u03b9 \u03c4\u03bf\u03c5 \u03b3\u03bb\u03bf\u03c5\u03ba\u03b1\u03b3\u03cc\u03bd\u03bf\u03c5 \u03c3\u03b5 \u03ac\u03c4\u03bf\u03bc\u03b1 \u03bc\u03b5 \u03a3\u03942", "Image ImageDescription": "\u2013 Time (min) GLP-1 infusion. Glucose (mg/dL) (n=10)   \u2013 Time (min) GLP-1 infusion. C-peptide (nmol/L) \u2013 Time (min)   GLP-1 infusion. Glucagon (pmol/L) In this study, a GLP-1 infusion normalized fasting plasma glucose in patients with poorly controlled T2DM.1. The subjects were 10 patients with T2DM in whom diet and medications had yielded unsatisfactory glycemic control. In the fasting state, they underwent intravenous infusion of saline or GLP-1. After less than 4 hours of GLP-1 treatment, plasma glucose (left) had fallen to normal fasting levels. At first, insulin levels increased significantly (P <.05), as reflected by rising C-peptide levels (middle). With glucose in the normal range, C-peptide levels dropped back toward baseline. Glucose levels remained stable despite continued GLP-1 infusion. Glucagon (right) levels were also significantly reduced (P <.05) during the GLP-1 infusion. Once plasma glucose approached normal fasting levels, glucagon returned to baseline values. These findings suggest not only that GLP-1 normalizes plasma glucose concentrations but also that the reduction in glucagon may itself play a role in this normalization process. Although the direct influence of glucose and the elevation of insulin concentrations can account for some of the effect on glucagon, in patients where insulin and C-peptide increased only slightly glucagon concentrations were still lowered. It is possible then, that the ability of GLP-1 to normalize plasma glucose is at least partially related to its ability to inhibit the \uf061-cell secretion of glucagon. Reference. 1. Nauck MA, Kleine N, \u00d8rskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non\u2013insulin-dependent) diabetic patients. Diabetologia. 1993;36:741\u2013744.  P <.05. \u2020GLP-1(7-36 amide) infused at 1.2 pmol/kg/min for 240 min. Adapted from Nauck MA, et al. Diabetologia. 1993;36:741\u2013744. GLP-1\u2020 Saline.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}